Industry News
Biotechnology Industry News
As biopharma M&A activity…
As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and
A brain tumor has prompted the FDA…
A brain tumor has prompted the FDA to put clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision. Regenxbio’s share price fell 32%
CalciMedica’s stock nosedived…
CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor in patients with acute kidney injury over a “safety concern.”
Boehringer Ingelheim has shared…
Boehringer Ingelheim has shared more phase 2 data on its kidney disease candidate apecotrep, shedding light on the decision to start a pivotal trial of the prospect last week.
Eli Lilly is continuing a run of…
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offerings by penning a pact with gene editing company Seamless Therapeutics.
Since launching one year ago with…
Since launching one year ago with a hearty $300 million series A, Kardigan has been on a biotech speedrun.
If the pursuit of Metsera signaled…
If the pursuit of Metsera signaled Novo Nordisk was ready to pay top dollar for the right innovation, the aftermath has filled Tamara Darsow’s calendar with high-stakes screenings for new opportunities.
The FDA is freeing Intellia’s…
The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister
Ahead of its acquisition by cancer…
Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.
Four years after listing on the…
Four years after listing on the Nasdaq, Genenta Sciences is taking the business in an unexpected direction.
Boehringer Ingelheim has penned a…
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody.
Roche’s dual GLP-1/GIP receptor…
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies in the coming weeks.
Qilu Pharmaceutical has struck a…
Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intelligence drug development capabilities, offering up to $120 million to collaborate on small molecules for treating cardiometabolic diseases.
European investment firm Gimv will…
European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its long-term investments and finding new value in four other key areas.
While 2025 was dedicated to…
While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said
What do you get when you insert a…
What do you get when you insert a molecular glue degrader into an antibody-drug conjugate? Fortitude Biomedicines is in the process of finding out.
Former CytoDyn CEO Nader…
Former CytoDyn CEO Nader Pourhassan, Ph.D., has received a 30-month prison sentence, or two and a half years, after being convicted on charges related to defrauding biotech investors.
AstraZeneca is showing no signs of…
AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its hometown, despite keeping its options open.
As the Trump administration erodes…
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
Despite remaining a fertile…
Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. hasn’t produced any new publicly listed drug developers of its own for many years.